GORE INITIATES THE RELIEF CLINICAL STUDY EVALUATING PFO CLOSURE FOR MIGRAINE HEADACHE RELIEF

CAUTION: Investigational device. Limited by United States law to investigational use.

Nov 1, 2022

Gore Completes First In-human Implants of the GORE® VIAFORT Vascular Stent

CAUTION: Investigational device. Limited by United States law to investigational use.W. L. Gore & Associates initiates its GORE® VIAFORT Device Pivotal Clinical Study for the treatment of inferior

Oct 28, 2022

GORE ACQUIRES INNAVASC MEDICAL, INC.

Acquisition of graft technology builds upon Gore’s dialysis access solutions

Aug 12, 2022

GORE RECEIVES FDA APPROVAL OF GORE® TAG® THORACIC BRANCH ENDOPROSTHESIS FOR THE REPAIR OF LESIONS OF THE DESCENDING THORACIC AORTA

Approval brings first flexible, off-the-shelf single-branch thoracic endoprosthesis for patients requiring zone 2 treatment.

May 13, 2022

GORE MEDICAL RECEIVES BREAKTHROUGH DEVICE DESIGNATION FOR THE GORE® EXCLUDER® THORACOABDOMINAL BRANCH ENDOPROSTHESIS

CAUTION: Investigational device. Limited by United States law to investigational use.

Apr 12, 2022

GORE® CARDIOFORM SEPTAL OCCLUDER MARKS 10 YEARS OF IMPROVING LIVES

After a decade of clinical use* and more than 50,000 devices sold globally, the GORE® CARDIOFORM Septal Occluder continues a trusted legacy of safely advancing care.

Jan 19, 2022

Gore Receives FDA Approval for the GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL System

The innovative device and delivery system combine proven conformability with new levels of control.

Jan 6, 2021